MIM Software Inc. Announces FDA Clearance of Contour ProtégéAI® 4.0 Models

MIM Software has received FDA clearance for updated contour models in Contour ProtégéAI®, its premier Radiation Oncology auto-segmentation software.

January 8, 2024

CLEVELAND, OH—May 10, 2023— MIM Software Inc., a leading global provider of medical imaging software, announced US Food and Drug Administration (FDA) clearance of its newest version of the AI auto-contouring solution Contour ProtégéAI. 

The update provides MIM Software® customers with iteratively improved algorithms for Radiation Oncology segmentation, additional structures, and enhancements for Molecular Radiotherapy (MRT).

With new FDA-cleared contours and the power of flexible implementation, Contour ProtégéAI can be added to any existing workflow with minimal effort and exceptional contouring results.

“Over the past several months, the MIM Software team has worked hard to focus this new version on improving our contouring performance,” said Jay Obman, Product Manager at MIM Software Inc. “The initial testing has shown a good improvement in our overall contour quality, and I’m excited for our users to reap the benefits of those improvements as well as some new contours we’ve added.”

To learn more about Contour ProtégéAI, click here

About MIM

About MIM

MIM Software, a GE HealthCare Company, makes vendor-neutral imaging software to standardize workflows in Radiation Oncology, Molecular Imaging, Theranostics, and more. Leading global healthcare organizations use MIM™ to simplify increasingly complex clinical scenarios and give patients more precise, personalized care.

Read More